Malaria Vaccine Development Using Synthetic Peptides as a Technical Platform

Advances in Immunology

Volumn 114, Issue , 2012, Pages 107-149

  Corradin, Giampietro ^a   Céspedes, Nora ^a,b   Verdini, Antonio ^a   Kajava, Andrey V ^c   Arévalo Herrera, Myriam ^b   Herrera, Sócrates ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSIDAD DEL VALLE   (Colombia)

^c Centre National de la Recherche Scientifique   (France)

Author keywords

Clinical trials; Immune response; Long Synthetic peptides; Malaria; Peptide synthesis; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GLUTAMIC ACID; GLUTAMIC ACID RICH PROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3 VACCINE; MONTANIDE ISA 51; SPF 66 VACCINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN STRUCTURE; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COVALENT BOND; CYTOKINE PRODUCTION; DEPROTECTION REACTION; DRUG EFFICACY; DRUG FORMULATION; EPITOPE MAPPING; GENE EXPRESSION SYSTEM; HUMAN; IMMUNOGENICITY; INFRARED SPECTROSCOPY; LIFE CYCLE STAGE; MALARIA; MALARIA FALCIPARUM; MEROZOITE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SCHIZONT; SOLID PHASE SYNTHESIS; SPOROZOITE; UNSPECIFIED SIDE EFFECT; VIRUS LIKE AGENT;

EID: 84858773353     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-396548-6.00005-6     Document Type: Chapter

References (217)

1. Alonso P.L., Tanner M., Smith T., Hayes R.J., Schellenberg J.A., Lopez M.C., Bastos de Azevedo I., Menendez C., Lyimo E., Weiss N., et al. A trial of the synthetic malaria vaccine SPf66 in tanzania: Rationale and design. Vaccine 1994, 12(2):181-186.
2. Alonso P.L., Ballou R., Brown G., Chitnis C., Loucq C., Moorthy V., Saul A., Wirth D. A research agenda for malaria eradication: Vaccines. PLoS Med. 2011, 8(1):e1000398.
3. Amador R., Moreno A., Murillo L.A., Sierra O., Saavedra D., Rojas M., Mora A.L., Rocha C.L., Alvarado F., Falla J.C., et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J. Infect. Dis. 1992, 166(1):139-144.
4. Aponte J.J., Menendez C., Schellenberg D., Kahigwa E., Mshinda H., Vountasou P., Tanner M., Alonso P.L. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 2007, 4(7):e242.
5. Arevalo-Herrera M., Roggero M.A., Gonzalez J.M., Vergara J., Corradin G., Lopez J.A., Herrera S. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann. Trop. Med. Parasitol. 1998, 92(5):539-551.
6. Arevalo-Herrera M., Valencia A.Z., Vergara J., Bonelo A., Fleischhauer K., Gonzalez J.M., Restrepo J.C., Lopez J.A., Valmori D., Corradin G., et al. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol. 2002, 24(3):161-169.
7. Arevalo-Herrera M., Chitnis C., Herrera S. Current status of Plasmodium vivax vaccine. Hum. Vaccin. 2010, 6(1):124-132.
8. Arevalo-Herrera M., Soto L., Perlaza B.L., Cespedes N., Vera O., Lenis A.M., Bonelo A., Corradin G., Herrera S. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Am. J. Trop. Med. Hyg. 2011, 84(2 Suppl.):35-42.
9. Arevalo-Herrera M., Vera O., Castellanos A., Cespedes N., Soto L., Corradin G., Herrera S. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am. J. Trop. Med. Hyg. 2011, 84(2 Suppl.):21-27.
10. Arnold L.A.L., Tyagi R.K., Meija P., Swetman C., Gleeson J., Perignon J.L., Druilhe P. Further improvements of the P. falciparum humanized mouse model. PLoS One 2011, 6(3).
11. Arnot D.E., Barnwell J.W., Tam J.P., Nussenzweig V., Nussenzweig R.S., Enea V. Circumsporozoite protein of Plasmodium vivax: Gene cloning and characterization of the immunodominant epitope. Science 1985, 230(4727):815-818.
12. Atherton E., Sheppard R.C. Solid Phase Peptide Synthesis. A Practical Approach 1989, IRL Press, Oxford.
13. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., Druilhe P., Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 2005, 73(12):8017-8026.
14. Audran R., Lurati-Ruiz F., Genton B., Blythman H.E., Ofori-Anyinam O., Reymond C., Corradin G., Spertini F. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: A randomized controlled phase I trial. PLoS One 2009, 4(10):e7304.
15. Baird J.K., Jones T.R., Danudirgo E.W., Annis B.A., Bangs M.J., Basri H., Purnomo, Masbar S. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am. J. Trop. Med. Hyg. 1991, 45(1):65-76.
16. Baird J.K., Masbar S., Basri H., Tirtokusumo S., Subianto B., Hoffman S.L. Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. J. Infect. Dis. 1998, 178(2):592-595.
17. Ballou W.R., Hoffman S.L., Sherwood J.A., Hollingdale M.R., Neva F.A., Hockmeyer W.T., Gordon D.M., Schneider I., Wirtz R.A., Young J.F., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987, 1(8545):1277-1281.
18. Bergman M., Zervas L. über ein allgemeinesVerfahren der peptid-synthese. Ber. Dtsch. Chem. Ges. 1932, 65:1192-1201.
19. Bernabeu M., Lopez F.J., Ferrer M., Martin-Jaular L., Razaname A., Corradin G., Maier A.G., del Portillo H.A., Fernandez-Becerra C. Functional analysis of Plasmodium vivax VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 endothelial receptor. Cell. Microbiol. 2011, [Epub ahead of print]. 10.1111/j.1462-5822.2011.01726.x.
20. Bisang C., Weber C., Inglis J., Schiffer C.A., Vangunsteren W.F., Jelesarov I., Bosshard H.R., Robinson J.A. Stabilization of type-I beta-turn conformations in peptides containing the npna-repeat motif of the plasmodium-falciparum circumsporozoite protein by substituting proline for (S)-alpha-methylproline. J. Am. Chem. Soc. 1995, 117(30):7904-7915.
21. Bisang C., Jiang L.Y., Freund E., Emery F., Bauch C., Matile H., Pluschke G., Robinson J.A. Synthesis, conformational properties, and immunogenicity of a cyclic template-bound peptide mimetic containing an NPNA motif from the circumsporozoite protein of Plasmodium falciparum. J. Am. Chem. Soc. 1998, 120(30):7439-7449.
22. Blum-Tirouvanziam U., Servis C., Habluetzel A., Valmori D., Men Y., Esposito F., Del Nero L., Holmes N., Fasel N., Corradin G. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J. Immunol. 1995, 154(8):3922-3931.
23. Bodanszky M. Synthesis of peptides by aminolysis of nitrophenyl esters. Nature 1955, 175(4459):685.
24. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 1990, 172(6):1633-1641.
25. Bouharoun-Tayoun H., Oeuvray C., Lunel F., Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 1995, 182(2):409-418.
26. Branch O., Casapia W.M., Gamboa D.V., Hernandez J.N., Alava F.F., Roncal N., Alvarez E., Perez E.J., Gotuzzo E. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malar. J. 2005, 4:27.
27. Brik A., Keinan E., Dawson P.E. Protein synthesis by solid-phase chemical ligation using a safety catch linker. J. Org. Chem. 2000, 65(12):3829-3835.
28. Brooks B.R., Pastor R.W., Carson F.W. Theoretically determined three-dimensional structure for the repeating tetrapeptide unit of the circumsporozoite coat protein of the malaria parasite Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 1987, 84(13):4470-4474.
29. Bruce M.C., Galinski M.R., Barnwell J.W., Donnelly C.A., Walmsley M., Alpers M.P., Walliker D., Day K.P. Genetic diversity and dynamics of Plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. Parasitology 2000, 121(Pt 3):257-272.
30. Burgess B.R., Schuck P., Garboczi D.N. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J. Biol. Chem. 2005, 280(44):37236-37245.
31. Canne L.E., Botti P., Simon R.J., Chen Y.J., Dennis E.A., Kent S.B.H. Chemical protein synthesis by solid phase ligation of unprotected peptide segments. J. Am. Chem. Soc. 1999, 121(38):8720-8727.
32. Carpino L.A. Oxidative reactions of hydrazines.4. Elimination of nitrogen from 1,1-disubstituted-2-arenesulfonhydrazides. J. Am. Chem. Soc. 1957, 79(16):4427-4431.
33. Carter R., Chen D.H. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature 1976, 263(5572):57-60.
34. Carter R., Mendis K. Transmission immunity in malaria: Reflections on the underlying immune mechanisms during natural infections and following artificial immunization. Mem. Inst. Oswaldo Cruz 1992, 87(Suppl. 3):169-173.
35. Cech P.G., Aebi T., Abdallah M.S., Mpina M., Machunda E.B., Westerfeld N., Stoffel S.A., Zurbriggen R., Pluschke G., Tanner M., et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: Randomized phase 1b trial in semi-immune adults & children. PLoS One 2011, 6(7):e22273.
36. Cerami C., Frevert U., Sinnis P., Takacs B., Clavijo P., Santos M.J., Nussenzweig V. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 1992, 70(6):1021-1033.
37. Chulay J.D. Development of sporozoite vaccines for malaria. Trans. R. Soc. Trop. Med. Hyg. 1989, 83(Suppl.):61-66.
38. Clyde D.F., McCarthy V.C., Miller R.M., Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973, 266(6):398-403.
39. Collin N., Dubois P.M. The vaccine formulation laboratory: A platform for access to adjuvants. Vaccine 2011, 29(Suppl. 1):A37-A39.
40. Collins W.E., Jeffery G.M., Roberts J.M. A retrospective examination of reinfection of humans with Plasmodium vivax. Am. J. Trop. Med. Hyg. 2004, 70(6):642-644.
41. Coppi A., Pinzon-Ortiz C., Hutter C., Sinnis P. The plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 2005, 201(1):27-33.
42. Coppi A., Natarajan R., Pradel G., Bennett B.L., James E.R., Roggero M.A., Corradin G., Persson C., Tewari R., Sinnis P. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 2011, 208(2):341-356.
43. Corradin G. Peptide based malaria vaccine development: Personal considerations. Microbes Infect. 2007, 9(6):767-771.
44. Corradin G., Spertini F., Verdini A. Medicinal application of long synthetic peptide technology. Expert Opin. Biol. Ther. 2004, 4(10):1629-1639.
45. Corradin G., Villard V., Kajava A.V. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr. Metab. Immune Disord. Drug Targets 2007, 7(4):259-265.
46. Corradin G., Kajava A.V., Verdini A. Long synthetic peptides for the production of vaccines and drugs: A technological platform coming of age. Sci. Transl. Med. 2010, 2(50):50rv3.
47. Curtius T. Ueber einige neue hippursäureanalog constituierte synthetisch dargestellte aminosauren. J. Prakt. Chemie 1882, 26:145-208.
48. Curtius T. Synthetische versuche mit hippurazid. Ber. Dtsch. Chem. Ges. 1902, 35:3226-3233.
49. D'Alessandro U., Leach A., Drakeley C.J., Bennett S., Olaleye B.O., Fegan G.W., Jawara M., Langerock P., George M.O., Targett G.A., et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995, 346(8973):462-467.
50. Dame J.B., Williams J.L., McCutchan T.F., Weber J.L., Wirtz R.A., Hockmeyer W.T., Maloy W.L., Haynes J.D., Schneider I., Roberts D., et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984, 225(4662):593-599.
51. Denkewalter R.G., Veber D.F., Holly F.W., Hirschmann R. Studies on total synthesis of an enzyme. I. Objective and strategy. J. Am. Chem. Soc. 1969, 91(2):502-503.
52. De Lano W.L. The PyMOL Molecular Graphics System 2002, De Lano Scientific, San Carlos, CA.
53. Doolan D.L., Dobano C., Baird J.K. Acquired immunity to malaria. Clin. Microbiol. Rev. 2009, 22(1):13-36. (Table of Contents).
54. Doolan D.L., Douradinha B., Roddick J., Robinson L., Taraika J., Mark D., Rarau P., Mueller I., Peters B., Sidney J., Sette A. Novel Antigen Discovery by Proteome-Wide Screening of CD4 and CD8 T Cell Epitopes Using P. falciparum as a Model 2011, (A. A. o. I. A. Meeting, Ed.), San Francisco, CA, USA.
55. Druilhe P., Spertini F., Soesoe D., Corradin G., Mejia P., Singh S., Audran R., Bouzidi A., Oeuvray C., Roussilhon C. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005, 2(11):e344.
56. Du Vigneaud V., Ressler C., Swan J.M., Roberts C.W., Katsoyannis P.G. The synthesis of oxytocin. J. Am. Chem. Soc. 1954, 76(12):3115-3121.
57. Du Y.C., Zhang Y.S., Lu Z.X., Tsou C.L. Resynthesis of insulin from its glycyl and phenylalanyl chains. Sci. Sin. 1961, 10(1):84-104.
58. Enea V., Ellis J., Zavala F., Arnot D.E., Asavanich A., Masuda A., Quakyi I., Nussenzweig R.S. DNA cloning of Plasmodium falciparum circumsporozoite gene: Amino acid sequence of repetitive epitope. Science 1984, 225(4662):628-630.
59. Engers H.D., Godal T. Malaria vaccine development: Current status. Parasitol. Today 1998, 14(2):56-64.
60. Esen M., Kremsner P.G., Schleucher R., Gassler M., Imoukhuede E.B., Imbault N., Leroy O., Jepsen S., Knudsen B.W., Schumm M., et al. Safety and immunogenicity of GMZ2-A MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009, 27(49):6862-6868.
61. Evans T.C., Benner J., Xu M.Q. Semisynthesis of cytotoxic proteins using a modified protein splicing element. Protein Sci. 1998, 7(11):2256-2264.
62. Facer C.A., Tanner M. Clinical trials of malaria vaccines: Progress and prospects. Adv. Parasitol. 1997, 39:1-68.
63. Feachem R.G.A., Phillips A.A., Targett G.A. Shrinking the Malaria Map: A Prospectus on Malaria Elimination 2009, The Global Health Group, San Francisco.
64. Fischer E. Synthese von derivaten der Polypeptid. Ber. Dtsch. Chem. Ges. 1903, 36:2094-2106.
65. Fischer E. Synthese von polypeptiden. XVII. Ber. Dtsch. Chem. Ges. 1907, 40:1754-1767.
66. Fischer E., Fourneau E. Ueber einige derivate des glykokolls. Ber.Dtsch. Chem. Ges. 1901, 34:2868-2879.
67. Franke E.D., Corradin G., Hoffman S.L. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. J. Immunol. 1997, 159(7):3424-3433.
68. Frevert U., Sinnis P., Cerami C., Shreffler W., Takacs B., Nussenzweig V. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J. Exp. Med. 1993, 177(5):1287-1298.
69. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., Carlton J.M., Pain A., Nelson K.E., Bowman S., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419(6906):498-511.
70. Genton B., Pluschke G., Degen L., Kammer A.R., Westerfeld N., Okitsu S.L., Schroller S., Vounatsou P., Mueller M.M., Tanner M., et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One 2007, 2(10):e1018.
71. Genton B., D'Acremont V., Lurati-Ruiz F., Verhage D., Audran R., Hermsen C., Wolters L., Reymond C., Spertini F., Sauerwein R. Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 2010, 28(40):6573-6580.
72. George F.W., Law J.L., Rich K.A., Martin W.J. Identification of a T-cell epitope on the circumsporozoite protein of Plasmodium vivax. Infect. Immun. 1990, 58(2):575-578.
73. Golenser J., Kamyl M., Tsafack A., Marva E., Cohen A., Kitrossky N., Chevion M. Correlation between destruction of malarial parasites by polymorphonuclear leukocytes and oxidative stress. Free Radic. Res. Commun. 1992, 17(4):249-262.
74. Gondeau C., Corradin G., Heitz F., Le Peuch C., Balbo A., Schuck P., Kajava A.V. The C-terminal domain of Plasmodium falciparum merozoite surface protein 3 self-assembles into alpha-helical coiled coil tetramer. Mol. Biochem. Parasitol. 2009, 165(2):153-161.
75. Gonzalez J.M., Peter K., Esposito F., Nebie I., Tiercy J.M., Bonelo A., Arevalo-Herrera M., Valmori D., Romero P., Herrera S., et al. HLA-a*0201 restricted CD8+ T-lymphocyte responses to malaria: Identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. Parasite Immunol. 2000, 22(10):501-514.
76. Gonzalez J.M., Hurtado S., Arevalo-Herrera M., Herrera S. Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates. Mem. Inst. Oswaldo Cruz 2001, 96(5):709-712.
77. Good M.F., Doolan D.L. Malaria vaccine design: Immunological considerations. Immunity 2010, 33(4):555-566.
78. Good M.F., Berzofsky J.A., Miller L.H. The T cell response to the malaria circumsporozoite protein: An immunological approach to vaccine development. Annu. Rev. Immunol. 1988, 6:663-688.
79. Grimaux E. Sur des colloides azotes. Bull. Soc. Chim. 1882, 38:64.
80. Gutte B., Merrifield R.B. Total synthesis of an enzyme with ribonuclease a activity. J. Am. Chem. Soc. 1969, 91(2):501-502.
81. Hackeng T.M., Fernandez J.A., Dawson P.E., Kent S.B., Griffin J.H. Chemical synthesis and spontaneous folding of a multidomain protein: Anticoagulant microprotein S. Proc. Natl. Acad. Sci. USA 2000, 97(26):14074-14078.
82. Harbury P.B., Zhang T., Kim P.S., Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 1993, 262(5138):1401-1407.
83. Hay S.I., Okiro E.A., Gething P.W., Patil A.P., Tatem A.J., Guerra C.A., Snow R.W. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med. 2010, 7(6):e1000290.
84. Hermsen C.C., Verhage D.F., Telgt D.S., Teelen K., Bousema J.T., Roestenberg M., Bolad A., Berzins K., Corradin G., Leroy O., et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007, 25(15):2930-2940.
85. Immune Responses to Parasitic Infections 2010, Bentham Science Publishers Ltd., CA, (Chapter 4). S. Herrera, M. Arevalo-Herrera (Eds.).
86. Herrera S., Escobar P., de Plata C., Avila G.I., Corradin G., Herrera M.A. Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein. J. Immunol. 1992, 148(12):3986-3990.
87. Herrera S., Herrera M.A., Corredor A., Rosero F., Clavijo C., Guerrero R. Failure of a synthetic vaccine to protect Aotus lemurinus against asexual blood stages of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1992, 47(5):682-690.
88. Herrera S., De Plata C., Gonzalez M., Perlaza B.L., Bettens F., Corradin G., Arevalo-Herrera M. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol. 1997, 19(4):161-170.
89. Herrera S., Bonelo A., Perlaza B.L., Valencia A.Z., Cifuentes C., Hurtado S., Quintero G., Lopez J.A., Corradin G., Arevalo-Herrera M. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int. J. Parasitol. 2004, 34(13-14):1535-1546.
90. Herrera S., Bonelo A., Perlaza B.L., Fernandez O.L., Victoria L., Lenis A.M., Soto L., Hurtado H., Acuna L.M., Velez J.D., et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am. J. Trop. Med. Hyg. 2005, 73(5 Suppl.):3-9.
91. Herrera S., Castellanos A., Arevalo-Herrera M., Restrepo N., Gulloso L., Corradin G. Plasmodium vivax thrombospondin related adhesion protein: Immunogenicity and protective efficacy in rodents and Aotus monkeys. Mem. Inst. Oswaldo Cruz 2007, 102(3):411-416.
92. Herrera S., Fernandez O., Manzano M.R., Murrain B., Vergara J., Blanco P., Palacios R., Velez J.D., Epstein J.E., Chen-Mok M., et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am. J. Trop. Med. Hyg. 2009, 81(5):740-746.
93. Herrera S., Fernandez O.L., Vera O., Cardenas W., Ramirez O., Palacios R., Chen-Mok M., Corradin G., Arevalo-Herrera M. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am. J. Trop. Med. Hyg. 2011, 84(2 Suppl.):12-20.
94. Herrera S., Solarte Y., Jordan-Villegas A., Echavarria J.F., Rocha L., Palacios R., Ramirez O., Velez J.D., Epstein J.E., Richie T.L., et al. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am. J. Trop. Med. Hyg. 2011, 84(2 Suppl.):4-11.
95. Herrington D.A., Clyde D.F., Losonsky G., Cortesia M., Murphy J.R., Davis J., Baqar S., Felix A.M., Heimer E.P., Gillessen D., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328(6127):257-259.
96. Herrington D., Davis J., Nardin E., Beier M., Cortese J., Eddy H., Losonsky G., Hollingdale M., Sztein M., Levine M., et al. Successful immunization of humans with irradiated malaria sporozoites-humoral and cellular-responses of the protected individuals. Am. J. Trop. Med. Hyg. 1991, 45(5):539-547.
97. Preventing sporozoite invasion of hepatocytes. Malaria Vaccine Development:A Multi-Inmune Responses Approach 1996, ASM Press. S. Hoffman (Ed.).
98. Hollingdale M.R., Nardin E.H., Tharavanij S., Schwartz A.L., Nussenzweig R.S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 1984, 132(2):909-913.
99. Jimenez-Diaz M.B., Mulet T., Viera S., Gomez V., Garuti H., Ibanez J., Alvarez-Doval A., Shultz L.D., Martinez A., Gargallo-Viola D., et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 2009, 53(10):4533-4536.
100. Jones T.R., Ballou W.R., Hoffman S.L. Antibodies to the circumsporozoite protein and protective immunity to malaria sporozoites. Prog. Clin. Parasitol. 1993, 3:103-117.
101. Kajava A.V. Review: Proteins with repeated sequence-Structural prediction and modeling. J. Struct. Biol. 2001, 134(2-3):132-144.
102. Kent S.B.H. New aspects of solid phase peptide synthesis. Biomedical Polymers 1980, Academic Press, San Diego. E.P. Goldberg, A. Nakajima (Eds.).
103. Kent S.B. Total chemical synthesis of proteins. Chem. Soc. Rev. 2009, 38(2):338-351.
104. Kharazmi A., Jepsen S., Andersen B.J. Generation of reactive oxygen radicals by human phagocytic cells activated by Plasmodium falciparum. Scand. J. Immunol. 1987, 25(4):335-341.
105. Kochar D.K., Das A., Kochar S.K., Saxena V., Sirohi P., Garg S., Kochar A., Khatri M.P., Gupta V. Severe Plasmodium vivax malaria: A report on serial cases from Bikaner in northwestern India. Am. J. Trop. Med. Hyg. 2009, 80(2):194-198.
106. Kochar S.K., Mahajan M., Gupta R.P., Middha S., Acharya J., Kochar A., Das A., Kochar D.K. Acute attack of AIP (acute intermittent porphyria) with severe vivax malaria associated with convulsions: A case report. J. Vector Borne Dis. 2009, 46(4):307-309.
107. Kochendoerfer G.G., Chen S.Y., Mao F., Cressman S., Traviglia S., Shao H., Hunter C.L., Low D.W., Cagle E.N., Carnevali M., et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 2003, 299(5608):884-887.
108. Kung Y.T., Du Y.C., Huang W.T., Chen C.C., Ke L.T., Hu S.C., Jiang R.Q., Chu S.Q., Niu C.I., Hsu J.Z., et al. Malaria Vaccine Development: 20 years of hopes, hypes and limited achievements. Total synthesis of crystalline bovine insulin. Sci. Sin. 1965, 14(11):1710-1716.
109. Lopez J.A., Weilenman C., Audran R., Roggero M.A., Bonelo A., Tiercy J.M., Spertini F., Corradin G. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 2001, 31(7):1989-1998.
110. Lusingu J.P., Gesase S., Msham S., Francis F., Lemnge M., Seth M., Sembuche S., Rutta A., Minja D., Segeja M.D., et al. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar. J. 2009, 8:163.
111. Lyon J.A., Thomas A.W., Hall T., Chulay J.D. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes. Mol. Biochem. Parasitol. 1989, 36(1):77-85.
112. Marsh K., Otoo L., Hayes R.J., Carson D.C., Greenwood B.M. Antibodies to blood stage antigens of Plasmodium-falciparum in rural gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 1989, 83(3):293-303.
113. Marshall V.M., Coppel R.L., Anders R.F., Kemp D.J. Two novel alleles within subfamilies of the merozoite surface antigen 2 (MSA-2) of Plasmodium falciparum. Mol. Biochem. Parasitol. 1992, 50(1):181-184.
114. McColl D.J., Anders R.F. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol. Biochem. Parasitol. 1997, 90(1):21-31.
115. McColl D.J., Silva A., Foley M., Kun J.F., Favaloro J.M., Thompson J.K., Marshall V.M., Coppel R.L., Kemp D.J., Anders R.F. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 1994, 68(1):53-67.
116. McGregor I.A. The passive transfer of human malarial immunity. Am. J. Trop. Med. Hyg. 1964, 13(Suppl.):237-239.
117. McGregor I.A., Turner M.W., Williams K., Hall P. Soluble antigens in the blood of African patients with severe Plasmodium falciparum malaria. Lancet 1968, 1(7548):881-884.
118. Mckay F.C., Albertson N.F. New amine-masking groups for peptide synthesis. J. Am. Chem. Soc. 1957, 79(17):4686-4690.
119. Mendis K.N., Munesinghe Y.D., de Silva Y.N., Keragalla I., Carter R. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect. Immun. 1987, 55(2):369-372.
120. Meraldi V., Nebie I., Tiono A.B., Diallo D., Sanogo E., Theisen M., Druilhe P., Corradin G., Moret R., Sirima B.S. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol. 2004, 26(6-7):265-272.
121. Merrifield R.B. Peptide synthesis on a solid polymer. Fed. Proc. 1962, 21(2):412.
122. Merrifield R.B. Solid phase peptide synthesis. 1. Synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85(14):2149.
123. Merrifield R.B. Life During a Golden Age of Peptide Chemistry: The Concept and Development of Solid-Phase Peptide Synthesis 1993, American Chemical Society, Washington, DC.
124. Merrifield R.B., Stewart J.M., Jernberg N. Instrument for automated synthesis of peptides. Anal. Chem. 1966, 38(13):1905-1914.
125. Migliorini P., Betschart B., Corradin G. Malaria vaccine: Immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity. Eur. J. Immunol. 1993, 23(2):582-585.
126. Mojsov S., Merrifield R.B. An improved synthesis of crystalline mammalian glucagon. Eur. J. Biochem. 1984, 145(3):601-605.
127. Mordmuller B., Szywon K., Greutelaers B., Esen M., Mewono L., Treut C., Murbeth R.E., Chilengi R., Noor R., Kilama W.L., et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine 2010, 28(41):6698-6703.
128. Moreno R., Jiang L., Moehle K., Zurbriggen R., Gluck R., Robinson J.A., Pluschke G. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2001, 2(11):838-843.
129. Morosan S., Hez-Deroubaix S., Lunel F., Renia L., Giannini C., Van Rooijen N., Battaglia S., Blanc C., Eling W., Sauerwein R., et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J. Infect. Dis. 2006, 193(7):996-1004.
130. Mueller M.S., Renard A., Boato F., Vogel D., Naegeli M., Zurbriggen R., Robinson J.A., Pluschke G. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 2003, 71(8):4749-4758.
131. Muir T.W., Sondhi D., Cole P.A. Expressed protein ligation: A general method for protein engineering. Proc. Natl. Acad. Sci. USA 1998, 95(12):6705-6710.
132. Muller H.M., Reckmann I., Hollingdale M.R., Bujard H., Robson K.J., Crisanti A. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J. 1993, 12(7):2881-2889.
133. Muller H.M., Scarselli E., Crisanti A. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum in parasite-host cell interactions. Parassitologia 1993, 35(Suppl.):69-72.
134. Nardin E. The past decade in malaria synthetic peptide vaccine clinical trials. Hum. Vaccin. 2010, 6(1):27-38.
135. Nardin E.H., Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: Role in protection and vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 1993, 11:687-727.
136. Nardin E.H., Herrington D.A., Davis J., Levine M., Stuber D., Takacs B., Caspers P., Barr P., Altszuler R., Clavijo P., et al. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 1989, 246(4937):1603-1606.
137. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Nussenzweig R.S., Schneider M., Tiercy J.M., Loutan L., Hochstrasser D., Rose K. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 2001, 166(1):481-489.
138. Nilsson B.L., Soellner M.B., Raines R.T. Chemical synthesis of proteins. Annu. Rev. Biophys. Biomol. Struct. 2005, 34:91-118.
139. Nishiuchi Y., Inui T., Nishio H., Bodi J., Kimura T., Tsuji F.I., Sakakibara S. Chemical synthesis of the precursor molecule of the Aequorea green fluorescent protein, subsequent folding, and development of fluorescence. Proc. Natl. Acad. Sci. USA 1998, 95(23):13549-13554.
140. Nosten F., Luxemburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E., Chongsuphajaisiddhi T., Gordon D.M., White N.J., Sadoff J.C., et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 1996, 348(9029):701-707.
141. Nussenzweig R. Use of radiation-attenuated sporozoites in the immunoprophylaxis of malaria. Int. J. Nucl. Med. Biol. 1980, 7(2):89-96.
142. Nussenzweig V., Nussenzweig R.S. Circumsporozoite proteins of malaria parasites. Bull. Mem. Acad. R. Med. Belg. 1989, 144(11):493-504.
143. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216(5111):160-162.
144. Oeuvray C., Bouharoun-Tayoun H., Gras-Masse H., Bottius E., Kaidoh T., Aikawa M., Filgueira M.C., Tartar A., Druilhe P. Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 84(5):1594-1602.
145. Oeuvray C., Theisen M., Rogier C., Trape J.F., Jepsen S., Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immun. 2000, 68(5):2617-2620.
146. Okitsu S.L., Silvie O., Westerfeld N., Curcic M., Kammer A.R., Mueller M.S., Sauerwein R.W., Robinson J.A., Genton B., Mazier D., et al. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One 2007, 2(12):e1278.
147. Olugbile S., Kulangara C., Bang G., Bertholet S., Suzarte E., Villard V., Frank G., Audran R., Razaname A., Nebie I., et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c. Infect. Immun. 2009, 77(12):5701-5709.
148. Olugbile S., Habel C., Servis C., Spertini F., Verdini A., Corradin G. Malaria vaccines-The long synthetic peptide approach: Technical and conceptual advancements. Curr. Opin. Mol. Ther. 2010, 12(1):64-76.
149. Olugbile S., Villard V., Bertholet S., Jafarshad A., Kulangara C., Roussilhon C., Frank G., Agak G.W., Felger I., Nebie I., et al. Malaria vaccine candidate: Design of a multivalent subunit alpha-helical coiled coil poly-epitope. Vaccine 2011, 29(40):7090-7099.
150. Overstreet M.G., Cockburn I.A., Chen Y.C., Zavala F. Protective CD8 T cells against Plasmodium liver stages: Immunobiology of an 'unnatural' immune response. Immunol. Rev. 2008, 225:272-283.
151. Pancake S.J., Holt G.D., Mellouk S., Hoffman S.L. Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates. J. Cell Biol. 1992, 117(6):1351-1357.
152. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 1989, 19(12):2237-2242.
153. Patarroyo M.E., Romero P., Torres M.L., Clavijo P., Moreno A., Martinez A., Rodriguez R., Guzman F., Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987, 328(6131):629-632.
154. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L.A., Ponton G., et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988, 332(6160):158-161.
155. Patarroyo G., Franco L., Amador R., Murillo L.A., Rocha C.L., Rojas M., Patarroyo M.E. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 1992, 10(3):175-178.
156. Perignon J.L., Druilhe P. Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Mem. Inst. Oswaldo Cruz 1994, 89(Suppl. 2):51-53.
157. Perlaza B.L., Sauzet J.P., Balde A.T., Brahimi K., Tall A., Corradin G., Druilhe P. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur. J. Immunol. 2001, 31(7):2200-2209.
158. Pink J.R., Sinigaglia F. Characterizing T-cell epitopes in vaccine candidates. Immunol. Today 1989, 10(12):408-409.
159. Plassmeyer M.L., Reiter K., Shimp R.L., Kotova S., Smith P.D., Hurt D.E., House B., Zou X., Zhang Y., Hickman M., et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 2009, 284(39):26951-26963.
160. Poland J.D., Calisher C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 1981, 59(6):895-900.
161. Price R.N., Douglas N.M., Anstey N.M. New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 2009, 22(5):430-435.
162. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., Plebanski M., Akinwunmi P., Everaere S., Watkins K.R., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 2004, 10(4):406-410.
163. Regnier F.E. High-performance liquid chromatography of proteins. Methods Enzymol. 1983, 91:137-190.
164. Renggli J., Valmori D., Romero J.F., Eberl G., Romero P., Betschart B., Corradin G. CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: Evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol. Lett. 1995, 46(1-2):199-205.
165. Renia L., Marussig M.S., Grillot D., Pied S., Corradin G., Miltgen F., Del Giudice G., Mazier D. In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. Proc. Natl. Acad. Sci. USA 1991, 88(18):7963-7967.
166. Reymond C.D., Beghdadi-Rais C., Roggero M., Duarte E.A., Desponds C., Bernard M., Groux D., Matile H., Bron C., Corradin G., et al. Anchoring of an immunogenic Plasmodium falciparum circumsporozoite protein on the surface of Dictyostelium discoideum. J. Biol. Chem. 1995, 270(21):12941-12947.
167. Rodriguez R., Moreno A., Guzman F., Calvo M., Patarroyo M.E. Studies in Owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of plasmodium-falciparum. Am. J. Trop. Med. Hyg. 1990, 43(4):339-354.
168. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., van de Vegte-Bolmer M., van Schaijk B., Teelen K., Arens T., et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 2009, 361(5):468-477.
169. Roggero M.A., Filippi B., Church P., Hoffman S.L., Blum-Tirouvanziam U., Lopez J.A., Esposito F., Matile H., Reymond C.D., Fasel N., et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol. Immunol. 1995, 32(17-18):1301-1309.
170. Roggero M.A., Meraldi V., Lopez J.A., Eberl G., Romero J.C., Matile H., Betschart B., Corradin G., Renggli J. The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response. Eur. J. Immunol. 2000, 30(9):2679-2685.
171. Romero P., Maryanski J.L., Cordey A.S., Corradin G., Nussenzweig R.S., Zavala F. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunol. Lett. 1990, 25(1-3):27-31.
172. Rose K. Facile synthesis of homogeneous artificial proteins. J. Am. Chem. Soc. 1994, 116(1):30-33.
173. Rose K., Zeng W., Brown L.E., Jackson D.C. A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Mol. Immunol. 1995, 32(14-15):1031-1037.
174. Rosenberg R., Wirtz R.A., Lanar D.E., Sattabongkot J., Hall T., Waters A.P., Prasittisuk C. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science 1989, 245(4921):973-976.
175. Roussilhon C., Oeuvray C., Muller-Graf C., Tall A., Rogier C., Trape J.F., Theisen M., Balde A., Perignon J.L., Druilhe P. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 2007, 4(11):e320.
176. Ruebush T.K., Campbell G.H., Moreno A., Patarroyo M.E., Collins W.E. Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens. Am. J. Trop. Med. Hyg. 1990, 43(4):355-366.
177. Salcedo M., Barreto L., Rojas M., Moya R., Cote J., Patarroyo M.E. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin. Exp. Immunol. 1991, 84(1):122-128.
178. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 2011, 11(1):57-64.
179. Schaal E. Ueber einige aus asparagisäure entstchende producte. Leibig's Annalen der Chemie 1871, 157:24-34.
180. Schneider J., Kent S.B. Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease. Cell 1988, 54(3):363-368.
181. Schnolzer M., Kent S.B. Constructing proteins by dovetailing unprotected synthetic peptides: Backbone-engineered HIV protease. Science 1992, 256(5054):221-225.
182. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., Nussenzweig V. Gamma-interferon, Cd8+ T-cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330(6149):664-666.
183. Schwyzer R. Coenzym-a-Modellversuche Zur Biologischen Acylierungsreaktion-Uber Die Reaktionsfahigkeit Von Thiolcarbonsauren Und Ihren Estern. Helvetica Chimica Acta 1953, 36(2):414-424.
184. Schwyzer R., Sieber P. Total synthesis of adrenocorticotrophic hormone. Nature 1963, 199(488):172.
185. Sedegah M., Sim B.K., Mason C., Nutman T., Malik A., Roberts C., Johnson A., Ochola J., Koech D., Were B., et al. Naturally acquired CD8+ cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. J. Immunol. 1992, 149(3):966-971.
186. Sheehan J.C., Hess G.P. A new method of forming peptide bonds. J. Am. Chem. Soc. 1955, 77(4):1067-1068.
187. Singh S., Soe S., Mejia J.P., Roussilhon C., Theisen M., Corradin G., Druilhe P. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J. Infect. Dis. 2004, 190(5):1010-1018.
188. Sinigaglia F., Guttinger M., Kilgus J., Doran D.M., Matile H., Etlinger H., Trzeciak A., Gillessen D., Pink J.R. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988, 336(6201):778-780.
189. Sinnis P., Nussenzweig V. Malaria Vaccine Development: A Multi-Immune Response Approach. Chapter 2. Preventing sporozoite Invasion of Hepatocytes 1996, American Society for Microbiology, Washington, DC. S. Hoffman (Ed.).
190. Sirima S.B., Nebie I., Ouedraogo A., Tiono A.B., Konate A.T., Gansane A., Derme A.I., Diarra A., Soulama I., Cuzzin-Ouattara N., et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007, 25(14):2723-2732.
191. Sirima S., Cousens S., Druilhe P. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med. 2011, 365(11):1062-1064.
192. Spaccapelo R., Naitza S., Robson K.J., Crisanti A. Thrombospondin-related adhesive protein (TRAP) of Plasmodium berghei and parasite motility. Lancet 1997, 350(9074):335.
193. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., Marchand M., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 1997, 336(2):86-91.
194. Sydor J.R., Mariano M., Sideris S., Nock S. Establishment of intein-mediated protein ligation under denaturing conditions: C-terminal labeling of a single-chain antibody for biochip screening. Bioconjug. Chem. 2002, 13(4):707-712.
195. Tam J.P., Clavijo P., Lu Y.A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 1990, 171(1):299-306.
196. Templeton T.J., Kaslow D.C. Cloning and cross-species comparison of the thrombospondin-related anonymous protein (TRAP) gene from Plasmodium knowlesi, Plasmodium vivax and Plasmodium gallinaceum. Mol. Biochem. Parasitol. 1997, 84(1):13-24.
197. Theisen M., Soe S., Oeuvray C., Thomas A.W., Vuust J., Danielsen S., Jepsen S., Druilhe P. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect. Immun. 1998, 66(1):11-17.
198. Theisen M., Soe S., Jessing S.G., Okkels L.M., Danielsen S., Oeuvray C., Druilhe P., Jepsen S. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 2000, 19(2-3):204-212.
199. Thierry A.C., Pinaud S., Bigler N., Perrenoud G., Denis B., Roggero M.A., Fasel N., Moulon C., Demotz S. Long synthetic peptides as biologically active proteins: The example of the chemokines. Biologicals 2001, 29(3-4):259-263.
200. Thompson F.M., Porter D.W., Okitsu S.L., Westerfeld N., Vogel D., Todryk S., Poulton I., Correa S., Hutchings C., Berthoud T., et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008, 3(1):e1493.
201. Tjitra E., Anstey N.M., Sugiarto P., Warikar N., Kenangalem E., Karyana M., Lampah D.A., Price R.N. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua, Indonesia. PLoS Med. 2008, 5(6):e128.
202. Unson C.G. Glucagon and the glucagon receptor: Merrifield years at the interface of chemistry and biology. Int. J. Pept. Res. Ther. 2007, 13(1-2):19-27.
203. Valero M.V., Amador L.R., Galindo C., Figueroa J., Bello M.S., Murillo L.A., Mora A.L., Patarroyo G., Rocha C.L., Rojas M., et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993, 341(8847):705-710.
204. Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 1992, 149(2):717-721.
205. Verdini A.S., Chiappinelli L., Zanobi A. Toward the elucidation of the mechanism of attachment and entry of malaria sporozoites into cells: Synthetic polypeptides from the circumsporozoite protein of Plasmodium falciparum bind Ca2+ and interact with model phospholipid membranes. Biopolymers 1991, 31(6):587-594.
206. Verdini A., Terenzi S., Brossard V., Roggero M., Corradin G. Oxidative folding of synthetic polypeptides S-protected as tert-butylthio derivatives. J. Pept. Sci. 2008, 14(12):1271-1282.
207. Verdini A., Olugbile S., Corradin G., Pink P. Malaria Vaccine Development: 20 Years of Hopes, Hypes and Limited Achievements. Immune Response to Parasitic Infections 2010, 21-42. Lausanne, Switzerland. E. Jirillo (Ed.).
208. Villard V., Agak G.W., Frank G., Jafarshad A., Servis C., Nebie I., Sirima S.B., Felger I., Arevalo-Herrera M., Herrera S., et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One 2007, 2(7):e645.
209. Weiss W.R., Berzofsky J.A., Houghten R.A., Sedegah M., Hollindale M., Hoffman S.L. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 1992, 149(6):2103-2109.
210. World Health Organization World Malaria Report: 2010 2010, WHO.
211. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: Re-assessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293(2):321-331.
212. Wünsch E. Synthesis of naturally occurring polypeptides, problems of current research. Angew. Chem. Int. Ed Engl. 1971, 10(11):786-795.
213. Wünsch E., Jaeger E., Scharf R. Zur synthese des glucagons. XIX Reindarstellung des synthetischen glucagons. Chem. Ber. 1968, 101:3664-3667.
214. Yajima H., Fujii N. Totally synthetic crystalline ribonuclease A. Biopolymers 1981, 20(9):1859-1867.
215. Zavala F., Tam J.P., Barr P.J., Romero P.J., Ley V., Nussenzweig R.S., Nussenzweig V. Synthetic peptide vaccine confers protection against murine malaria. J. Exp. Med. 1987, 166(5):1591-1596.
216. Zhang Y.S. The first protein ever synthesized in vitro-A personal reminiscence of the total synthesis of crystalline insulin. Sci. China Life Sci. 2010, 53(1):16-18.
217. Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 2003, 21(9-10):921-924.